- Home
- MUR vs CRSP Comparison
MUR vs CRSP Comparison
Compare MUR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUR
- CRSP
- Stock Information
- Founded
- MUR 1950
- CRSP 2013
- Country
- MUR United States
- CRSP Switzerland
- Employees
- MUR N/A
- CRSP N/A
- Industry
- MUR Oil & Gas Production
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MUR Energy
- CRSP Health Care
- Exchange
- MUR Nasdaq
- CRSP Nasdaq
- Market Cap
- MUR 3.1B
- CRSP 3.8B
- IPO Year
- MUR N/A
- CRSP 2016
- Fundamental
- Price
- MUR $23.15
- CRSP $46.83
- Analyst Decision
- MUR Hold
- CRSP Buy
- Analyst Count
- MUR 15
- CRSP 17
- Target Price
- MUR $28.42
- CRSP $71.20
- AVG Volume (30 Days)
- MUR 3.1M
- CRSP 3.3M
- Earning Date
- MUR 08-07-2025
- CRSP 08-04-2025
- Dividend Yield
- MUR 5.62%
- CRSP N/A
- EPS Growth
- MUR N/A
- CRSP N/A
- EPS
- MUR 2.61
- CRSP N/A
- Revenue
- MUR $2,896,480,000.00
- CRSP $37,675,000.00
- Revenue This Year
- MUR N/A
- CRSP $30.25
- Revenue Next Year
- MUR $5.60
- CRSP $268.62
- P/E Ratio
- MUR $8.73
- CRSP N/A
- Revenue Growth
- MUR N/A
- CRSP N/A
- 52 Week Low
- MUR $18.95
- CRSP $30.04
- 52 Week High
- MUR $43.02
- CRSP $63.68
- Technical
- Relative Strength Index (RSI)
- MUR 50.16
- CRSP 70.33
- Support Level
- MUR $22.41
- CRSP $43.23
- Resistance Level
- MUR $25.38
- CRSP $48.48
- Average True Range (ATR)
- MUR 0.96
- CRSP 2.31
- MACD
- MUR -0.15
- CRSP 0.57
- Stochastic Oscillator
- MUR 30.65
- CRSP 79.99
About MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.